Why the study?
Does sulfinpyrazone improve platelet survival time and inhibit serotonin release in patients with previous myocardial infarction?
Does sulfinpyrazone improve platelet survival time and inhibit serotonin release in patients with previous myocardial infarction?
Sulfinpyrazone appears to prevent the reduction in platelet survival time seen in hyperbetalipoproteinemic patients after myocardial infarction, likely via inhibition of the release reaction.
Suggests sulfinpyrazone may preserve platelet survival in hyperbetalipoproteinemic post-MI patients; extends antiplatelet observations to lipid subgroups.
Preliminary data obtained in the ambit of Anturan Reinfarction Italian Study (ARIS) show that, in postmyocardial infarction, reduced platelet survival time occurred in hyperbetalipoproteinemic patients treated with placebo, but not in the group of patients treated with sulfinpyrazone (interaction between treatment and lipemic level is at p approximately equal to 0.1). The sulfinpyrazone effect on platelet survival is probably related to the release reaction inhibition as suggested by our ex vivo results on platelet-bound 14C-serotonin release.
No takes yet. Share an insight, caveat, or question.
Cortellaro et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: